Back to search results

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California Los Angeles, Los Angeles, California, United States

  • Orlando Health, Orlando, Florida, United States

  • Emory University School of Medicine, Atlanta, Georgia, United States

  • St. Elizabeth Healthcare, Edgewood, Kentucky, United States

  • Norton Cancer Institute, Louisville, Kentucky, United States

  • Henry Ford Cancer Institute/Henry Ford Health System, Detroit, Michigan, United States

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States

  • Ohio State University, Columbus, Ohio, United States

  • Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States

  • University of Tennessee Medical Center, Knoxville, Tennessee, United States

  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

  • Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, United States

  • Renovatio Clinical, The Woodlands, Texas, United States

  • Inova Schar Cancer Institute, Fairfax, Virginia, United States

  • Wide Bay Hospital and Health Service - Cancer Care Services - Bundaberg, Bundaberg, Queensland, Australia

  • Peter MacCallum Cancer Centre (PMCC), Melbourne, Victoria, Australia

  • Centre Jean Perrin, Clermont-Ferrand, Auvergne-Rhône, France

  • Timone Hospital - AP-HM, Marseille, Bordeaux, France

  • Hopital Europeen Geroges Pompidou AP-HP, Paris, Île-de-France Region, France

  • Istituto Europeo di Oncologia, Milan, Italy

  • Hospital Universitario Virgen del Rocio, Seville, Andalusia, Spain

  • Hospital Clinic, Barcelona, Catalonia, Spain

  • Hospital Universitario de Navarra, Pamplona, Navarre, Spain

  • Centro Oncologico de Galicia, A Coruña, Spain

  • Hospital Universitario La Paz, Madrid, Spain

Study leads

  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)